Cytochrome P-450 CYP2C19 Inhibitors

Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP2C19.

Also Known As:

CYP2C19 Inhibitors; P450 CYP2C19 Inhibitors; Cytochrome P 450 CYP2C19 Inhibitors; Inhibitors, CYP2C19; Inhibitors, P450 CYP2C19

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

1.	Body Weight (Weight, Body) 02/01/2009 - "Body weight, SIRS, age, hepatic dysfunction and presence of CYP2C19 inhibitors were significant covariates affecting clearance (CL), accounting for 75% of interindividual variability. " 11/01/2023 - "For sertraline, CYP2C19 phenotype and concomitant CYP2C19 inhibitors influenced CL/F, and empirical allometric scaling of patient body weight on CL/F and V/F was significant. "
2.	Infections 05/01/2011 - "The frequency of mutant CYP2C19 forms with decreased function (from 2% of Caucasians to 30% of Asians and 79% of certain Polynesians), together with common use of CYP2C19 inhibitors in the alloSCT process, creates risk for impaired pentamidine clearance resulting in toxicity ordinarily expected only with high doses given for active infection. "
3.	Hypothermia 03/01/2019 - "This report describes clobazam-associated hypothermia due to supratherapeutic serum concentrations of clobazam that resulted from the combination of 2 CYP2C19 inhibitors."
4.	Gastroesophageal Reflux (GERD) 12/17/2016 - "The phenoconversion after 30 d of PPI therapy in GERD patients was statistically significant (p =0.001) with omeprazole/esomeprazole (n = 27) strong CYP2C19 inhibitors, while there was no change in CYP2C19 enzyme activity (p = 0.8) with pantoprazole/ rabeprazole (n = 27), weak CYP2C19 inhibitors. "

1.	Therapeutics